Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 2
1995 1
1997 7
1998 13
1999 25
2000 21
2001 49
2002 48
2003 33
2004 53
2005 79
2006 70
2007 75
2008 78
2009 75
2010 68
2011 61
2012 65
2013 71
2014 72
2015 50
2016 43
2017 51
2018 54
2019 37
2020 34
2021 28
2022 26
2023 27
2024 20

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,181 results

Results by year

Filters applied: . Clear all
Page 1
Tolterodine Tartrate.
Ananchenko G, Novakovic J. Ananchenko G, et al. Profiles Drug Subst Excip Relat Methodol. 2017;42:339-403. doi: 10.1016/bs.podrm.2017.02.007. Epub 2017 Mar 30. Profiles Drug Subst Excip Relat Methodol. 2017. PMID: 28431780
Tolterodine tartrate belongs to the family of muscarinic receptor antagonists and is indicated for the treatment of overactive urinary bladder syndrome. This chapter provides an overview of physical, analytical, and ADME profiles; highlights methods of chemical synt …
Tolterodine tartrate belongs to the family of muscarinic receptor antagonists and is indicated for the treatment of overactive …
International Phase III, Randomized, Double-Blind, Placebo and Active Controlled Study to Evaluate the Safety and Efficacy of Vibegron in Patients with Symptoms of Overactive Bladder: EMPOWUR.
Staskin D, Frankel J, Varano S, Shortino D, Jankowich R, Mudd PN Jr. Staskin D, et al. J Urol. 2020 Aug;204(2):316-324. doi: 10.1097/JU.0000000000000807. Epub 2020 Feb 18. J Urol. 2020. PMID: 32068484 Clinical Trial.
MATERIALS AND METHODS: Adult patients with overactive bladder with 8.0 or more micturitions per day were randomized 5:5:4 to 75 mg vibegron, placebo or extended-release 4 mg extended-release tolterodine. Up to 25% of patients could have dry overactive bladder (less than 1. …
MATERIALS AND METHODS: Adult patients with overactive bladder with 8.0 or more micturitions per day were randomized 5:5:4 to 75 mg vibegron, …
Comparative assessment of efficacy and safety of approved oral therapies for overactive bladder: a systematic review and network meta-analysis.
He W, Huang G, Cui W, Tian Y, Sun Q, Zhao X, Zhao Y, Li D, Liu X. He W, et al. Int Braz J Urol. 2023 Sep-Oct;49(5):535-563. doi: 10.1590/S1677-5538.IBJU.2023.0158. Int Braz J Urol. 2023. PMID: 37506033 Free PMC article. Review.
In terms of safety, solifenacin 5mg, ER-tolterodine 4mg, mirabegron, vibegron and ER-oxybutynin 10mg all showed a better incidence of dry mouth, fesoterodine 4mg, ER-oxybutynin 10mg, tolterodine 2mg, and vibegron in the incidence of constipation. ...
In terms of safety, solifenacin 5mg, ER-tolterodine 4mg, mirabegron, vibegron and ER-oxybutynin 10mg all showed a better incidence of …
Editorial comment.
Yang SS. Yang SS. J Urol. 2009 Oct;182(4 Suppl):2038-9; discussion 2039. doi: 10.1016/j.juro.2009.05.162. Epub 2009 Aug 20. J Urol. 2009. PMID: 19695625 No abstract available.
Tolterodine extended-release for overactive bladder.
Chung DE, Te AE. Chung DE, et al. Expert Opin Pharmacother. 2009 Sep;10(13):2181-94. doi: 10.1517/14656560903167965. Expert Opin Pharmacother. 2009. PMID: 19663610 Review.
Recent literature strongly supports the efficacy and safety of tolterodine ER in carefully selected older men with OAB symptoms. Tolterodine ER is well tolerated and withdrawal rates are similar to those in placebo. Fesoterodine is a new antimuscarinic that shares t …
Recent literature strongly supports the efficacy and safety of tolterodine ER in carefully selected older men with OAB symptoms. T …
Tolterodine in the Treatment of Male LUTS.
Gacci M, Sebastianelli A, Salvi M, Schiavina R, Brunocilla E, Novara G, De Nunzio C, Tubaro A, Oelke M, Gravas S, Carini M, Serni S. Gacci M, et al. Curr Urol Rep. 2015 Sep;16(9):60. doi: 10.1007/s11934-015-0531-9. Curr Urol Rep. 2015. PMID: 26149965 Review.
In order to improve compliance with oral drug treatment, tolterodine was developed, providing a better efficacy/adverse event profile. Tolterodine is available in the following two formulations: the intermediate release (IR) and extended release form (ER). Tolter …
In order to improve compliance with oral drug treatment, tolterodine was developed, providing a better efficacy/adverse event profile …
Tolterodine-induced hyponatraemia.
Juss JK, Radhamma AK, Forsyth DR. Juss JK, et al. Age Ageing. 2005 Sep;34(5):524-5. doi: 10.1093/ageing/afi131. Age Ageing. 2005. PMID: 16107463
We believe this is the first case report of hyponatraemia due to tolterodine....
We believe this is the first case report of hyponatraemia due to tolterodine....
Tolterodine: a clinical review.
Crandall C. Crandall C. J Womens Health Gend Based Med. 2001 Oct;10(8):735-43. doi: 10.1089/15246090152636488. J Womens Health Gend Based Med. 2001. PMID: 11703885 Review.
This analysis reviews clinical trials of the efficacy and safety of tolterodine for use in overactive bladder. It also compares the safety and efficacy of tolterodine and previously available pharmacotherapy. ...Studies ranged from 2 to 12 weeks in duration. Nine tr …
This analysis reviews clinical trials of the efficacy and safety of tolterodine for use in overactive bladder. It also compares the s …
Editorial Comment.
Malik RD. Malik RD. J Urol. 2019 Sep;202(3):572. doi: 10.1097/01.JU.0000558552.60504.d8. Epub 2019 Aug 8. J Urol. 2019. PMID: 31166883 No abstract available.
Tolterodine: an overview.
Wefer J, Truss MC, Jonas U. Wefer J, et al. World J Urol. 2001 Nov;19(5):312-8. doi: 10.1007/s003450100224. World J Urol. 2001. PMID: 11760779 Review.
Tolterodine has emerged as a new anticholinergic drug to treat detrusor instability in recent years. ...A new extended release formula of tolterodine has been launched that may improve patients' compliance....
Tolterodine has emerged as a new anticholinergic drug to treat detrusor instability in recent years. ...A new extended release formul …
1,181 results